高纯度尿促性素对不同年龄卵巢储备功能减退患者体外受精的影响

Abstract
Figure/Table
References (25)
Related Citation (1)

Download: PDF (559 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective To investigate the effect of highly purified human menopausal gonadotropin (HP-hMG) on in vitro fertilization-embryo transfer in patients with diminished ovarian reserve (DOR) at different ages. Methods A total of 133 DOR patients from Handan Central Hospital of Hebei Province from July 2015 to December 2019 were selected, and they were divided into recombinant follicle stimulating hormone group (group A, 67 cases) and HP-hMG group (group B, 66 cases) according to treatment regimen; the two groups were further divided according to age (<35 years or ≥35 years), the ovarian response and pregnancy outcomes of the two groups at different ages were compared. Results Patients aged <35 years old: the amount of gonadotropin (Gn) in group B was higher than that in group A, and estrogen (E2) level on trigger day was lower than that in group A, with statistical significances (P < 0.05). There were no significant differences in cumulative pregnancy rate and cumulative live birth rate between two groups (P > 0.05). Patients aged ≥35 year old: the amount of Gn and top quality embryo rate in group B were higher than those in group A, E2 level on trigger day and egg number obtained were lower than those in group A, with statistical significances (P < 0.05). There were no significant differences in cumulative pregnancy rate and cumulative live birth rate between two groups (P > 0.05). Conclusion HP-hMG can significantly improve top quality embryo rate of DOR patients ≥35 years old.

Key words： Highly purified human menopausal gonadotrophin Diminished ovarian reserve Controlled ovarian stimulation Top quality embryo

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	ZHAO Haijun1 LU Jing1 ZHANG Yijiao1▲ WANG Yuhong1 CHEN Jing1 JING Li1 CHANG Yueting2 ZHANG Hongfeng3

Cite this article:

ZHAO Haijun1 LU Jing1 ZHANG Yijiao1▲ WANG Yuhong1 CHEN Jing1 JING Li1 CHANG Yueting2 ZHANG Hongfeng3. Effect of highly purified human menopausal gonadotrophin on in vitro fertilization in patients with diminished ovarian reserve at different ages#br#[J]. 中国医药导报, 2021, 18(33): 111-114.

URL:

https://www.yiyaodaobao.com.cn/EN/ OR https://www.yiyaodaobao.com.cn/EN/Y2021/V18/I33/111

[1] Ata B，Seyhan A，Seli E. Diminished ovarian reserve versus ovarian aging：overlaps and differences [J]. Curr Opin Obstet Gynecol，2019，31（3）：139-147.
[2] Bar Hava I，Blueshtein M，Ganer Herman H，et al. Gonad-otropin relea sing hormone analogue as sole luteal support in antagonist-based assisted reproductive technology cycles [J]. Fertil Steril，2017，107（1）：130-135.e1.
[3] Nazari L，Salehpour S，Hosseini S，et al. Effect of myo-inositol supplementation on ICSI outcomes among poor ovarian responder patients：A randomized controlled trial [J]. J Gynecol Obstet Hum Reprod，2020，49（5）：101698.
[4] 曾倩凌，燕怡，李艳萍，等.高孕激素状态下促排卵与微刺激方案在卵巢储备功能下降患者中的临床结局及经济效益比较[J].中国临床研究，2020，33（7）：908-912.
[5] 包莉莉，杨波，王冬雪，等.高纯度人绝经期促性腺激素的应用对IVF/ICSI促排卵中鲜胚移植率的影响[J].生殖医学杂志，2019，28（10）：1179-1183.
[6] 田东梅，李亨利，朱明辉，等.卵巢储备正常者COH不同阶段添加高纯度人绝经期促性腺激素对IVF-ET结局的影响[J].生殖与避孕，2016，36（9）：769-773.
[7] 李方凤.重组人卵泡刺激素与尿促性素对多囊卵巢综合征患者体外受精周期促排卵效果比较[J].中国妇幼保健，2017，32（3）：569-571.
[8] 沈浣，罗旭飞，吴丹.《中国高龄不孕女性辅助生殖临床实践指南》解读[J].实用妇产科杂志，2020，36（5）：350-353.
[9] 李园园.年轻DOR与同龄卵巢储备功能正常患者IVF比较[J].中国优生与遗传杂志，2020，28（5）：644-645.
[10] 吴畏，刘嘉茵.卵巢储备功能减退患者助孕方案的选择[J].中国实用妇科与产科杂志，2015，31（8）：726-730.
[11] Ferraretti AP，La Marca A，Fauser BC，et al. ESHRE consensus on the definition of‘poor response’ to ovarian stimulation for in vitro fertilization：the Bologna criteria [J]. Hum Reprod，2011，26：1616-1624.
[12] 中华医学会生殖医学分会.中国高龄不孕女性辅助生殖临床实践指南[J].中国循证医学杂志，2019，19（3）：253-270.
[13] Leijdekkers JA，Eijkemans MJC，van Tilborg TC，et al. Cumulative live birth rates in low-prognosis women [J]. Hum Reprod，2019，34（6）：1030-1041.
[14] 王凤，邓伟芬，廖海珍，等.改良超长方案中促排卵时不同时期添加高纯度尿促性素对助孕结局的影响[J].中华生殖与避孕杂志，2017，37（1）：16-21.
[15] Witz CA，Daftary GS，Doody KJ，et al. Randomized，assessor-blinded trial comparing highly purified human menotropin and recombinant follicle-stimulating hormone in high responders undergoing intracytoplasmic sperm injection [J]. Fertil Steril，2020，114（2）：321-330.
[16] 杨永俊，李铭，曹丽幸，等.来曲唑联合高纯度尿促性素治疗对多囊卵巢综合征不孕患者妊娠效果的影响及激素调节作用[J].中国合理用药探索，2021，18（9）：85-89.
[17] Deeks ED. Highly Purified Human Menopausal Gonadotropin （Menopur?誖）：A Profile of Its Use in Infertility [J]. Clin Drug Investig，2018，38（11）：1077-1084.
[18] 刘景瑜，王玢，孙海翔.PCOS患者体外受精周期r-FSH和HP-HMG促排卵临床结局的比较[J].实用妇产科杂志，2014，32（4）：291-294.
[19] Weiss G，Skurnick JH，Goldsmith LT，et al. Menopause and hypothalamic-pituitary sensitivity to estrogen [J]. JAMA，2004，292（24）：2991-2996.
[20] Errázuriz J，Romito A，Drakopoulos P，et al. Cumulative Live Birth Rates Following Stimulation With Corifollitropin Alfa Compared With hp-hMG in a GnRH Antagonist Protocol in Poor Ovarian Responders [J]. Front Endocrinol （Lausanne），2019，10：175.
[21] Sousa M，Cunha M，Teixeira da Silva J，et al. Ovarian hyperstimulation syndrome：a clinical report on 4 894 consecutive ART treatment cycles [J]. Reprod Biol Endocrinol，2015，13（1）：66
[22] Santi D，Casarini L，Alviggi C，et al. Efficacy of Follicle-Stimulating Hormone （FSH） Alone， FSH + Luteinizing Hormone，Human Menopausal Gonadotropin or FSH + Human Chorionic Gonadotropin on Assisted Reproductive Technology Outcomes in the “Personalized” Medicine Era：A Meta-analysis [J]. Front Endocrinol （Lausanne），2017，8：114.
[23] Casarini L，Santi D，Brigante G，et al. Two Hormones for One Receptor：Evolution，Biochemistry，Actions，and Pathophysiology of LH and hCG [J]. Endocr Rev，2018，39（5）：549-592.
[24] Riccetti L，Yvinec R，Klett D，et al. Human Luteinizing Hormone and Chorionic Gonadotropin Display Biased Agonism at the LH and LH/CG Receptors[J]. Sci Rep，2017，7（1）：940.
[25] Smitz J，Platteau P. Influence of human chorionic gonadotrophin during ovarian stimulation：an overview [J]. Reprod Biol Endocrinol，2020，18（1）：80.